Vor Biopharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VOR research report →
Range $27 – $31
Price Chart
About the company
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials.
- CEO
- Jean-Paul Kress
- IPO
- 2021
- Employees
- 76
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on VOR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.01B
- P/E
- -0.06
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -5.03
- EV/EBITDA
- 1.40
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -91.63%
- ROIC
- -32.21%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-371,642,000
- Net Income
- $-695,981,000-495.3%
- EPS
- $-70.50-107.4%
- OCF Growth
- -43.2%
- FCF Growth
- -43.8%
- 52W High
- $35.82
- 52W Low
- $6.50
- 50D MA
- $21.96
- 200D MA
- $16.78
- Beta
- 1.72
- RSI (14)
- 37
- Avg Volume
- 1.03M
No earnings-call transcripts are available for VOR yet.
- Free Float
- 520.4%
- Shares Outstanding
- 54.19M
- Float Shares
- 281.98M
of shares held by institutions
105 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tcg Crossover Management, LLC | 5.67M | 0 |
| Fmr LLC | 4.93M | ▲ 3.39M |
| Fcpm Iii Services B.V. | 4.12M | 0 |
| Blackrock, Inc. | 3.47M | ▲ 2.67M |
| Vr Adviser, LLC | 3.04M | 0 |
| State Street Corp | 2.62M | ▲ 1.50M |
| Frazier Life Sciences Management, L.P. | 2.54M | 0 |
| Ra Capital Management, L.P. | 2.40M | ▼ 3.00M |
| Vanguard Capital Management LLC | 2.08M | ▲ 651.05K |
| Caligan Partners LP | 1.93M | 0 |
| Paradigm Biocapital Advisors LP | 1.75M | 0 |
| Great Point Partners LLC | 1.70M | ▼ 50.00K |
Held by 192 ETFs
Biggest fund positions in VOR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 2, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 500 |
| Oct 2, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 500 |
| Aug 24, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 1,500 |
| Aug 24, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 1,500 |
| Jul 16, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 2,100,000 |
| Jul 16, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 2,100,000 |
| Jul 16, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 213 |
| Jul 7, 26 | ZACCARDELLI DAVID | other | 0 |
| Jul 7, 26 | ZACCARDELLI DAVID | other | 42,658 |
| Jun 11, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 57,162 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VOR coverage
Recent articles, reports, and earnings notes.
No research on VOR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VOR report →Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 5
Vor Biopharma (NASDAQ:VOR) Shares Up 5.3% – What’s Next?
defenseworld.net · Oct 2
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
globenewswire.com · Sep 29
Vor Biopharma: A Funded Replication Story With Franchise Potential
seekingalpha.com · Sep 18
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com · Sep 9
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
globenewswire.com · Sep 8
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 4
Bank of America Corp DE Has $2.01 Million Stock Holdings in Vor Biopharma Inc. $VOR
defenseworld.net · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.